Risk Partners Life Sciences Roundtable 2025, thank you very much! 

OLG Schleswig: Limitation of the liability claim
in the case of a direct claim in the D&O insurance.

There is a new, exciting ruling from the world of D&O insurance. We recently reported on the decision of the Higher Regional Court of Cologne in the context of direct action. Now the Higher Regional Court of Schleswig has also made a groundbreaking decision.

What was it about? The focus was on the question of the statute of limitations. However, it must be borne in mind that the question of the limitation period in D&O claims is not trivial. On the one hand, there is the original claim for damages (statutory directors' and officers' liability separate from the D&O insurance) as well as a claim under cover law that arises between the parties - insurer, insured persons and insured companies - due to the conclusion of the D&O insurance. Now both the claim for damages and the contractual claims under the D&O insurance can become time-barred. If the limitation period for the claim under cover law is now suspended by filing a direct claim or a direct action with the insurer, what does this mean for the necessary liability claim? Can an insurer release itself from liability in this case if the claim is already time-barred? The decision of the Higher Regional Court of Schleswig has now clarified this question.

Zum Hintergrund: Ein Brand in einer Bäckerei verursachte einen erheblichen Schaden, von dem die Feuerversicherung, berechtigterweise aufgrund der Vertragsbedingungen, nur einen Teil übernahm. (Hinweis: Daher empfehlen wir, die Versicherungssummen sowie die inhaltliche Gestaltung des Versicherungsschutzes regelmäßig zu dokumentieren und zu überprüfen.) Der Betreiber der Bäckerei machte den Restschaden geltend, indem er den Geschäftsführer wegen Pflichtverletzung verantwortlich machte. Infolgedessen trat der Geschäftsführer seinen Freistellungsanspruch aus der D&O-Versicherung an die Gesellschaft ab (siehe dazu die beigefügte Grafik). Eine D&O-Versicherung deckt üblicherweise Führungskräfte eines Unternehmens ab. Im Schadensfall müssen Ansprüche zunächst gegenüber der versicherten Person geltend gemacht werden, bevor sie gegen den Versicherer durchgesetzt werden können. Dies resultiert oft in komplexen und zeitaufwändigen Haftungs- und Deckungsrechtsstreitigkeiten. In der Praxis wird der Streit immer häufiger in einem Direktprozess geführt, durch das Abtreten des Freistellungsanspruchs der versicherten Person an die Versicherungsnehmerin. Dadurch kann die Versicherungsnehmerin ihre Ansprüche direkt gegen den Versicherer geltend machen. Zur Entscheidung: Das OLG Schleswig hat in seinem Urteil vom 26.02.2024 (Az. 16 U 93/23) festgehalten, dass durch diese Abtretung des Freistellungsanspruchs eine “Waffenstillstandsvereinbarung” (pactum de non petendo) implizit geschlossen wurde. Diese Vereinbarung verhindert einen Haftungsprozess gegen den Geschäftsführer, solange der Anspruch gegen den Versicherer besteht, und hemmt die Verjährung der gesetzlichen Haftungsansprüche. Die deckungsrechtliche Hemmung durch Einreichung einer Direktklage oder eines Direktanspruches beim Versicherer hemmt also ebenfalls die gesetzliche Verjährung.

The ruling by the Higher Regional Court of Schleswig fundamentally strengthens the position of companies that wish to take direct action against their D&O insurers. It deprives insurers of a further opportunity to reject claims without an indemnification. This makes it more attractive to take direct action against the D&O insurer rather than against the responsible managers. In addition to the transfer of control by the manager concerned, especially in the case of an assignment on account of performance in accordance with section 364(2) of the German Civil Code (BGB), there are other aspects to consider. These include, for example, the effects on public limited companies under the strict AG regime and, in principle, the disadvantages associated with the "direct action", such as contractual insurance obligations in the event of a claim. For this reason, Risk Partners will continue to closely monitor developments relating to direct action on behalf of our clients. We at Risk Partners will stay on the ball for you.

Also read our other blog posts

Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
Being Public

Earnings Call: one 0 too many - the Lyft CEO mistake

"Look, it was a bad mistake, and that's on me," CEO of LYFT Inc. The incident and possible insurance coverage. You may have also heard about the recent incident with LYFT. In the quarterly earnings report, LYFT originally stated that profit margins were up 500 basis points before correcting this to 50 basis points during the conference call. This clerical error caused the stock price to rise more than 60% in after-hours trading. This situation is exactly what investor relations teams that

Read more "
4 pillars of cyber insurance for venture capital and private equity
Cyber Security

Cyber insurance Venture capital and private equity

Why cyber insurance does not transfer the core risk of VC & PE funds and why we have invested in Risk Partners cyber master agreements. Why cyber risks are relevant for venture capital and private equity funds With the increasing growth of the cyber crime industry (see Federal Office for the Protection of the Constitution), venture capital (VC) and private equity (PE) funds and their fund managers are also increasingly exposed to cyber risks. For years, this has been reflected in the claims we have been able to support, in which fund managers have ranked first year after year among the industries we advise.

Read more "
IPO

Risk Partners is advising Terranor Group AG on its NASDAQ (Sweden) IPO

From Road Builder to IPO Candidate: How Terranor Group AB Conquered Nasdaq First North. It was a day that marked a new chapter not only for Terranor Group AB but for the entire Nordic infrastructure sector: On June 19, 2025, the Swedish company celebrated its successful initial public offering on the Nasdaq First North Premier Growth Market in Stockholm. Risk Partners as IPO Advisor For while Terranor Group shares began trading under the ticker symbol TERNOR on June 30, 2025,

Read more "
Life Sciences

Finance Day 2024

Growth capital for biotechnology and life sciences - Finance Day 2024 A few days ago, Jutta and Florian from our team attended Finance Day 2024 at the analytica trade fair in Munich. The event once again offered exciting expert panels on current financing and capital market issues for life sciences companies. As the panels focused on three of our key consulting areas, namely life sciences, venture capital and IPOs, attending was of course a must for us as a specialist insurance broker. Our team was also very pleased to meet many of our partners and clients again.

Read more "
Being Public

"I believe in a strong IPO comeback in 2024" - Interview Platform Life Sciences

Risk Partners in the trade press. Florian was approached by the journalists from Plattform Life Sciences for an interview on our view of 2024 and the development of Risk Partners over the past year. In addition to challenging claims, product innovations (e.g. all about POSI insurance) from Risk Partners, Florian also discusses our motives for the "team up" with the fantastic colleagues from Atrialis GmbH - experts in clinical trials. Click here for Florian's interview. Read the interview

Read more "